Disease Detail

ID DOID:1996
Name rectum adenocarcinoma
Definition A rectum cancer that derives_from epithelial cells of glandular origin.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer rectum cancer rectum adenocarcinoma
Path disease disease of anatomical entity gastrointestinal system disease gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer rectum cancer rectum adenocarcinoma
Path disease disease of anatomical entity gastrointestinal system disease intestinal disease intestinal cancer large intestine cancer colorectal cancer rectum cancer rectum adenocarcinoma
Path disease disease of cellular proliferation cancer cell type cancer carcinoma adenocarcinoma rectum adenocarcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
APC Q1429fs BRAF N581S ERBB2 L755S Fluorouracil + Leucovorin + Trastuzumab rectum adenocarcinoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00602329 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer Unknown status
NCT00967655 Phase II Capecitabine + Panitumumab Irinotecan Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer Unknown status
NCT01206530 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab Hydroxychloroquine FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Completed
NCT01282502 Phase I Midostaurin Midostaurin (PKC412) for Locally Advanced Rectal Cancer Completed
NCT01298570 Phase II FOLFIRI Regorafenib Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer Active, not recruiting
NCT01442935 Phase II Bevacizumab + FOLFOX Cetuximab + FOLFIRI Bevacizumab + FOLFIRI Cetuximab + FOLFOX Bevacizumab + FOLFIRINOX Cetuximab + FOLFIRINOX Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases Active, not recruiting
NCT01471353 Phase II Sorafenib + Capecitabine Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer Completed
NCT01516216 Phase II Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Study of Vitamin D in Untreated Metastatic Colorectal Cancer Active, not recruiting
NCT01538680 Phase III Regorafenib Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy No longer available
NCT01571284 Phase III Aflibercept + FOLFIRI Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Completed
NCT01634685 Phase I Bavituximab + Capecitabine A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma Completed
NCT01652482 Phase II Cetuximab MEHD7945A FOLFIRI A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed
NCT01803282 Phase I GS-5745 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed FOLFIRI Nab-paclitaxel + Gemcitabine Paclitaxel + Carboplatin Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Active, not recruiting
NCT01814501 Phase II FOLFIRI Panitumumab Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab Recruiting
NCT01871571 Phase II Bevacizumab + FOLFOX Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer Active, not recruiting
NCT01896856 Phase Ib/II Guadecitabine + Irinotecan Regorafenib Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer Recruiting
NCT01939223 Phase III Regorafenib COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST) Terminated
NCT01949194 Phase II Regorafenib Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Active, not recruiting
NCT02008383 Phase I Panitumumab + cabozantinib Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer Completed
NCT02045030 Phase II Aflibercept + FOLFIRI Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Terminated
NCT02046538 Phase II FOLFIRI Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Aflibercept Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer Withdrawn
NCT02096354 Phase II Regorafenib A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer Active, not recruiting
NCT02119676 Phase II Regorafenib Ruxolitinib Study of Ruxolitinib in Colorectal Cancer Patients Terminated
NCT02138617 Phase II Leucovorin Bevacizumab Irinotecan Fluorouracil Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer Recruiting
NCT02164916 Phase II Cetuximab + Irinotecan Vemurafenib + Cetuximab + Irinotecan S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Active, not recruiting
NCT02178644 Phase I KD018 Capecitabine Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer Active, not recruiting
NCT02195011 Phase II Regorafenib Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases Completed
NCT02287727 Phase II Regorafenib Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment Withdrawn
NCT02305758 Phase II FOLFIRI Bevacizumab Veliparib Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer Completed
NCT02368886 Phase II Clobetasol + Regorafenib Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer Active, not recruiting
NCT02393755 Phase Ib/II Capecitabine + Nintedanib Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer Active, not recruiting
NCT02550743 Phase I BYL719 + Capecitabine BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study Terminated
NCT02575508 Phase Ib/II BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer Withdrawn
NCT02651415 Phase II Perindopril + Regorafenib Phase II Study of Perindopril and Regorafenib in mCRC Active, not recruiting
NCT02688712 Phase II Capecitabine + Galunisertib Fluorouracil + Galunisertib Galunisertib Fluorouracil Capecitabine ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer Recruiting
NCT02788279 Phase III Atezolizumab Atezolizumab + Cobimetinib Regorafenib A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma Completed
NCT02921256 Phase II Veliparib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Capecitabine + Veliparib Capecitabine Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer Recruiting
NCT02935309 Phase I Capecitabine + Lenvatinib Phase I Study of Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma Recruiting
NCT02972034 Phase I MK-8353 + Pembrolizumab Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) Recruiting
NCT02997228 Phase III Atezolizumab Bevacizumab + FOLFOX Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer Recruiting
NCT03043313 Phase II Trastuzumab + Tucatinib Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER)Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER) (MOUNTAINEER) Recruiting
NCT03053544 Phase II Metformin Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer Recruiting
NCT03102047 Phase II Durvalumab Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer Recruiting
NCT03261947 Phase II TAK-931 A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Recruiting
NCT03365882 Phase II Cetuximab + Irinotecan Pertuzumab + Trastuzumab S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Recruiting
NCT03368859 Phase II ABT-165 + FOLFIRI Bevacizumab + FOLFIRI A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab Recruiting
NCT03436563 Phase Ib/II M7824 M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer Recruiting
NCT03592641 Phase II Savolitinib Volitinib in Treating Participants With MET Amplified Metastatic or Unresectable Colorectal Cancer Not yet recruiting
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Recruiting
NCT03801915 Phase II MVT-5873 Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Not yet recruiting
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Recruiting
NCT03866239 Phase I Atezolizumab + Obinutuzumab + RO6958688 A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma Recruiting